Skip to main
CBIO

GlycoMimetics Inc (CBIO) Stock Forecast & Price Target

GlycoMimetics Inc (CBIO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Crescent Biopharma is a promising biopharmaceutical company with a strong pipeline featuring CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody, and two potential blockbuster ADC programs in CR-002 and CR-003. The risks to achieving our price target and rating for CBIO include clinical and regulatory failures for CR-001, potential commercial challenges, and potential M&A risks. However, we view CR-001 as a promising clinical asset and remain interested in Crescent's other programs.

Bears say

Crescent Biopharma is a biopharmaceutical company with a focus on developing therapeutics for solid tumors. While their pipeline product CR-001 may have the potential for improved clinical efficacy and safety, the recent Phase 3 clinical trial results comparing it to ivonescimab (a bispecific anti-PD-1/anti-VEGF antibody) showed similar efficacy. Additionally, there are concerns about the company's ability to compete with other oncology therapies, such as Keytruda and LM-299, which could limit their potential sales and market share.

GlycoMimetics Inc (CBIO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GlycoMimetics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GlycoMimetics Inc (CBIO) Forecast

Analysts have given GlycoMimetics Inc (CBIO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, GlycoMimetics Inc (CBIO) has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GlycoMimetics Inc (CBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.